CompletedNot Applicable

Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)

8,790 participantsStarted 2011-11

Plain-language summary

The purpose of this study is to determine the proportion of participants that initiate allergen immunotherapy (AIT) upon the recommendation of their physician and the proportion of participants that persist with their AIT throughout the recommended course.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of AR with or without allergic conjunctivitis (AC) * Documented provider-to-patient or parent discussion of AIT as a treatment option Exclusion Criteria: * Participants receiving AIT as an AR treatment without documented provider-to-patient or parent discussion of AIT as a treatment option * Participants receiving immunotherapy for insect sensitivities only * AIT started before 2005

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage of Participants Advised to Start AIT Who Elected Subcutaneous Immunotherapy (SCIT) Shots or Sublingual Immunotherapy (SLIT) Drops

Timeframe: Up to 5 years

Percentage of Participants Who Initiated SCIT or SLIT and Completed 5 Years of Treatment

Timeframe: At 5 years

Duration of Treatment With SCIT or SLIT

Timeframe: Up to 5 years

Reason for Discontinuation of SCIT or SLIT More Than 6 Months Before Completion of the Recommended Course

Timeframe: Up to 5 years

Trial details

NCT IDNCT01549340

SponsorALK-Abelló A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2012-05

Results submitted2014-01-23

View on ClinicalTrials.gov More Perennial Allergic Rhinitis trials

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Percentage of Participants Advised to Start AIT Who Elected Subcutaneous Immunotherapy (SCIT) Shots or Sublingual Immunotherapy (SLIT) Drops

Timeframe: Up to 5 years

Percentage of Participants Who Initiated SCIT or SLIT and Completed 5 Years of Treatment

Timeframe: At 5 years

Duration of Treatment With SCIT or SLIT

Timeframe: Up to 5 years

Reason for Discontinuation of SCIT or SLIT More Than 6 Months Before Completion of the Recommended Course

Timeframe: Up to 5 years